WASHINGTON: Alexion Pharmaceuticals Inc said on Thursday its experimental drug to treat patients with a rare blood disorder met the main goal in a late-stage study, sending its shares up 18 percent in premarket trading.
The drug, ALXN1210, was being tested against the company’s flagship drug, Soliris, in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). The company said the drug demonstrated non-inferiority to Soliris on the main goal as well as four of the key secondary goals. Alexion said it expects to file marketing application for the drug in the United States, the European Union and Japan in the second half of 2018.
Veteran cricket journalist Sharda Ugra said the sport is used as a vehicle for a muscular nationalism
The UAE saw record rainfall with 254 mm falling in less than 24 hours in Al Ain, a city on the UAE-Oman border
Prime Minister Anthony Albanese singled Guerot out for praise on Tuesday
The bill passed a vote in Britain’s parliament with 383 in favour and 67 against
The Supreme Court has previously refused to accept two formal apologies from Ramdev and his firm’s co-founder...
